Advertisement

Obesity Surgery

, Volume 27, Issue 1, pp 78–82 | Cite as

TSH Normalization in Bariatric Surgery Patients After the Switch from l-Thyroxine in Tablet to an Oral Liquid Formulation

  • Poupak Fallahi
  • Silvia Martina Ferrari
  • Stefania Camastra
  • Ugo Politti
  • Ilaria Ruffilli
  • Roberto Vita
  • Giuseppe Navarra
  • Salvatore Benvenga
  • Alessandro AntonelliEmail author
Original Contributions

Abstract

Objective

Drug malabsorption is one of the potential troubles after bariatric surgery. Evidence for diminished levothyroxine (L-T4) absorption has been reported in patients after bariatric surgery.

Methods

This study reports 17 cases of hypothyroid patients [who were well replaced with thyroxine tablets (for >1 year) to euthyroid thyrotropin (TSH) levels before surgery (13 Roux-en-Y gastric bypasses (RYGB); 4 biliary pancreatic diversions (BPD))]. From 3 to 8 months after surgery, these patients had elevated TSH levels. Patients were then switched from oral tablets to a liquid L-T4 formulation (with the same dosage, 30 min before breakfast).

Results

Two–three months after the switch, TSH was significantly reduced both in patients treated with RYGB, as in those treated with BPD, while FT4 and FT3 levels were not significantly changed (RYGB group, TSH μIU/mL: 7.58 ± 3.07 vs 3.808 ± 1.83, P < 0.001; BPD group, TSH μIU/mL: 8.82 ± 2.76 vs 3.12 ± 1.33, P < 0.01).

Conclusions

These results first show that liquid L-T4 could prevent the problem of malabsorption in patients with BPD and confirm those of previous studies in patients submitted to RYGB, suggesting that the L-T4 oral liquid formulation could circumvent malabsorption after bariatric surgery.

Keywords

Bariatric surgery Roux-en-Y gastric bypass Biliary pancreatic diversion Levothyroxine malabsorption Liquid L-T4 Hypothyroidism 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 2009;19(12):1605–11. PMID: 19885707.CrossRefPubMedGoogle Scholar
  2. 2.
    Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427–36. PMID: 23338049.CrossRefPubMedGoogle Scholar
  3. 3.
    Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol. 2015;11(8):465–77. PMID: 26055046.CrossRefPubMedGoogle Scholar
  4. 4.
    Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016. PMID: 26868660.Google Scholar
  5. 5.
    Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. Diabetes Care. 2005;28(2):481–4. PMID: 15677821.CrossRefPubMedGoogle Scholar
  6. 6.
    Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63(19):1852–7. PMID: 16990631.CrossRefPubMedGoogle Scholar
  7. 7.
    Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50. PMID: 19493300.CrossRefPubMedGoogle Scholar
  8. 8.
    Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16(1):73–8. PMID: 16487017.CrossRefPubMedGoogle Scholar
  9. 9.
    Moulin de Moraes CM, Mancini MC, de Melo ME, et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg. 2005;15(9):1287–91. PMID: 16259889.CrossRefPubMedGoogle Scholar
  10. 10.
    Galofré JC, Pujante P, Abreu C, et al. Relationship between thyroid-stimulating hormone and insulin in euthyroid obese men. Ann Nutr Metab. 2008;53(3–4):188–94. PMID: 19011282.CrossRefPubMedGoogle Scholar
  11. 11.
    Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am. 2012;96(2):369–83. PMID: 22443981.CrossRefPubMedGoogle Scholar
  12. 12.
    Almandoz JP, Gharib H. Hypothyroidism: etiology, diagnosis, and management. Med Clin North Am. 2012;96(2):203–21. PMID: 22443971.CrossRefPubMedGoogle Scholar
  13. 13.
    Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):174–80. PMID: 25461470.CrossRefPubMedGoogle Scholar
  14. 14.
    Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med. 1987;316(13):764–70. PMID: 3821822.CrossRefPubMedGoogle Scholar
  15. 15.
    Eledrisi MS, Szymajda A, Alshanti M, et al. Noncompliance with medical treatment: pseudomalabsorption of levothyroxine. South Med J. 2001;94(8):833–6. PMID: 11549198.CrossRefPubMedGoogle Scholar
  16. 16.
    Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105–10. PMID: 18996189, Epub 2008 Nov 1.CrossRefPubMedGoogle Scholar
  17. 17.
    Sherman SI, Malecha SE. Absorption and malabsorption of levothyroxine sodium. Am J Ther. 1995;2(10):814–8. PMID: 11854792.CrossRefPubMedGoogle Scholar
  18. 18.
    Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787–95. PMID: 16641395.CrossRefPubMedGoogle Scholar
  19. 19.
    Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med. 1993;119(6):492–502. PMID: 8357116.CrossRefPubMedGoogle Scholar
  20. 20.
    Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009;23(6):781–92. PMID: 19942153.CrossRefPubMedGoogle Scholar
  21. 21.
    Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–60. PMID: 18474247.CrossRefPubMedGoogle Scholar
  22. 22.
    Checchi S, Montanaro A, Pasqui L, et al. L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab. 2008;93(2):465–9. PMID: 18042648.CrossRefPubMedGoogle Scholar
  23. 23.
    Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345–9. PMID: 17669709.CrossRefPubMedGoogle Scholar
  24. 24.
    Azizi F, Belur R, Albano J. Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Ann Intern Med. 1979;90(6):941–2. PMID: 443690.CrossRefPubMedGoogle Scholar
  25. 25.
    Bevan JS, Munro JF. Thyroxine malabsorption following intestinal bypass surgery. Int J Obes. 1986;10(3):245–6. PMID: 3759332.PubMedGoogle Scholar
  26. 26.
    Pirola I, Formenti AM, Gandossi E, et al. Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes Surg. 2013;23(9):1493–6. PMID: 23824980.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Camastra S, Gastaldelli A, Mari A, et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia. 2011;54(8):2093–102. PMID: 21614570.CrossRefPubMedGoogle Scholar
  28. 28.
    Scopinaro N, Gianetta E, Civalleri D, et al. Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg. 1979;66(9):618–20. PMID: 497645.CrossRefPubMedGoogle Scholar
  29. 29.
    Lee S, Farwell AP. Euthyroid sick syndrome. Compr Physiol. 2016;6(2):1071–80. PMID: 27065175.CrossRefPubMedGoogle Scholar
  30. 30.
    Carswell KA, Belgaumkar AP, Amiel SA, Patel AG. A systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg. 2015. PMID: 26210195Google Scholar
  31. 31.
    Padwal RS, Lewanczuk RZ. Trends in bariatric surgery in Canada, 1993–2003. CMAJ. 2005;172(6):735. PMID: 15767602.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Pontiroli AE, Laneri M, Veronelli A, et al. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc Diabetol. 2009;8:37. PMID: 19619292.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Saraceno G, Vita R, Trimarchi F, et al. A liquid formulation of L- thyroxine (L-T4) solves problems of incomplete normalization/suppression of serum TSH caused by proton pump inhibitors (PPI) on conventional tablet formulations of L-T4. Presented at European Society of Endocrinology ICE/ECE 2012 May Florence, Italy. Endocr Abstr. 2012;29:P1626.Google Scholar
  34. 34.
    Vita R, Fallahi P, Antonelli A, et al. The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv. 2014;11(7):1103–11. PMID: 24896369.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002;41(9):661–80. PMID: 12126458.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Poupak Fallahi
    • 1
  • Silvia Martina Ferrari
    • 1
  • Stefania Camastra
    • 1
  • Ugo Politti
    • 1
  • Ilaria Ruffilli
    • 1
  • Roberto Vita
    • 2
  • Giuseppe Navarra
    • 3
  • Salvatore Benvenga
    • 2
  • Alessandro Antonelli
    • 1
    Email author
  1. 1.Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  2. 2.Department of Clinical and Experimental Medicine, Section of EndocrinologyUniversity of MessinaMessinaItaly
  3. 3.Department of Human PathologyUniversity Hospital of MessinaMessinaItaly

Personalised recommendations